Sanofi S.A. (SNY)
Stock Price Chart
Key Info
| Market Cap | 126.88B |
| Revenue (ttm) | 44.47B |
| Net Income (ttm) | 3.32B |
| Shares Out | 2.51B |
| EPS (ttm) | 1.94 |
| PE Ratio | 26.03 |
| Forward PE | 14.71 |
| Dividend | $1.70 |
| Dividend Yield | 3.37% |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $50.50 |
| Previous Close | $51.37 |
| Change ($) | -0.88 |
| Change (%) | -1.70% |
| Day's Open | 50.60 |
| Day's Range | 50.40 - 50.75 |
| Day's Volume | 543,272 |
| 52-Week Range | 37.62 - 55.00 |
More Stats
| Market Cap | 126.88B |
| Enterprise Value | 146.39B |
| Earnings Date (est) | Oct 29, 2020 |
| Ex-Dividend Date | Apr 30, 2020 |
| Shares Outstanding | 2.51B |
| Float | 2.23B |
| EPS (basic) | n/a |
| EPS (diluted) | 1.94 |
| FCF / Share | 3.38 |
| Dividend | $1.70 |
| Dividend Yield | 3.37% |
| Earnings Yield | 3.84% |
| FCF Yield | 6.66% |
| Payout Ratio | n/a |
| Shares Short | 3.69M |
| Short Ratio | 3.88 |
| Short % of Float | n/a |
| Beta | 0.47 |
| PE Ratio | 26.03 |
| Forward PE | 14.71 |
| P/FCF Ratio | 15.01 |
| PS Ratio | 2.85 |
| PB Ratio | 1.75 |
| Revenue | 44.47B |
| Operating Income | 3.69B |
| Net Income | 3.32B |
| Free Cash Flow | 8.45B |
| Net Cash | -19.51B |
| Net Cash / Share | -7.76 |
| Gross Margin | 68.18% |
| Operating Margin | 8.30% |
| Profit Margin | 7.50% |
| FCF Margin | 19.01% |
| ROA | 4.00% |
| ROE | 18.62% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37,631 | 35,677 | 36,221 | 34,696 | 34,861 | 31,999 | 31,291 | 35,957 | 35,058 | 34,036 |
| Revenue Growth | 5.48% | -1.5% | 4.4% | -0.47% | 8.94% | 2.26% | -12.98% | 2.56% | 3% | - |
| Gross Profit | 25,655 | 24,242 | 24,608 | 23,995 | 23,942 | 21,769 | 20,989 | 24,859 | 24,193 | 24,638 |
| Operating Income | 3,125 | 4,676 | 5,804 | 6,666 | 5,571 | 6,367 | 4,668 | 6,622 | 5,846 | 6,535 |
| Net Income | 2,806 | 4,306 | 8,416 | 4,709 | 4,287 | 4,390 | 3,716 | 4,888 | 5,646 | 5,467 |
| Shares Outstanding | 1,250 | 1,247 | 1,257 | 1,287 | 1,306 | 1,316 | 1,323 | 1,320 | 1,322 | 1,305 |
| Earnings Per Share | 1.12 | 1.72 | 3.32 | 1.82 | 1.63 | 1.65 | 1.39 | 1.84 | 2.13 | 2.09 |
| EPS Growth | -34.99% | -48.34% | 82.92% | 11.69% | -1.52% | 19.13% | -24.73% | -13.62% | 1.91% | - |
| Dividend Per Share | 1.74 | 1.79 | 1.05 | 1.63 | 1.62 | 1.91 | 1.86 | 1.69 | 1.32 | 1.10 |
| Dividend Growth | -2.9% | 69.92% | -35.34% | 0.74% | -15.29% | 2.58% | 10.18% | 28.03% | 20% | - |
| Operating Cash Flow | 7,744 | 5,547 | 7,379 | 8,184 | 8,920 | 7,690 | 6,954 | 8,171 | 9,319 | 9,859 |
| Capital Expenditures | -592 | 186 | -1,421 | -1,874 | -2,561 | -1,191 | -898 | -1,254 | -1,423 | -1,526 |
| Free Cash Flow | 7,152 | 5,733 | 5,958 | 6,310 | 6,359 | 6,499 | 6,056 | 6,917 | 7,896 | 8,333 |
| Cash & Equivalents | 9,427 | 6,925 | 10,315 | 10,273 | 9,148 | 7,341 | 8,442 | 6,559 | 4,297 | 6,516 |
| Total Debt | 25,933 | 24,640 | 15,601 | 18,579 | 16,554 | 14,814 | 14,590 | 14,531 | 15,439 | 8,260 |
| Net Cash / Debt | -16,506 | -17,715 | -5,286 | -8,306 | -7,406 | -7,473 | -6,148 | -7,972 | -11,142 | -1,744 |
| Assets | 112,736 | 111,408 | 99,813 | 104,679 | 102,321 | 97,392 | 96,055 | 100,399 | 100,672 | 85,264 |
| Liabilities | 53,628 | 52,373 | 41,574 | 46,957 | 44,111 | 41,124 | 39,022 | 42,913 | 44,309 | 31,976 |
| Book Value | 58,934 | 58,876 | 58,070 | 57,552 | 58,049 | 56,120 | 56,904 | 57,352 | 56,193 | 53,097 |
Company Profile
Company Details
| Full Name | Sanofi S.A. |
| Country | France |
| Employees | 100,409 |
| CEO | Paul Hudson |
Stock Information
| Ticker Symbol | SNY |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NASDAQ: SNY |
Description
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.